Literature DB >> 16848106

Bone mineral density in survivors of childhood acute lymphoblastic leukemia.

Fani Athanassiadou1, Athanassios Tragiannidis, Israel Rousso, Georgios Katsos, Vassiliki Sidi, Theodotis Papageorgiou, Christos Papastergiou, Ioannis Tsituridis, Dimitrios Koliouskas.   

Abstract

The aim of our study was to evaluate bone metabolism with measurement of bone mineral density (BMD) after management (chemo-, radiotherapy) for childhood acute lymphoblastic leukemia (ALL). Bone mineral density (g/cm2) of lumbar spine was measured by dual energy X-ray absorptiometry (Norland bone densitometer) in 18 children with ALL and a median of 34 months' post-diagnosis with no history of relapse, secondary malignancy, or transplantation. In addition, patients' BMDs were correlated with particular attention to age, sex and time (years) from completion of chemotherapy. The results were compared with healthy age- and sex-matched controls of the same population and expressed as standard deviation scores (SDS). Mean age of children was 9.8 +/- 3.7 years. Of 18 children (10 boys and 8 girls), 13 were grouped as standard and 5 as high-risk, respectively. Based on z-score values, 9 were classified as normal (z-score <1 SD), 7 as osteopenic (z-score 1-2.5 SD) and 2 as osteoporotic (z-score >2.5 SD). Children with ALL had reduced lumbar BMDs (z score -0.99) in comparison to healthy controls (z score -0.14) (p=0.011), which is indicative of relative osteopenia. Moreover, the reduced BMD was associated with patient age (z score -0.14 and -1.52 for ages <10 and >10 years, respectively, p=0.016). Reduced BMD was not correlated with time from completion of chemotherapy (p=0.33), risk group (p=0.9) and sex (p=0.3). We conclude that children's BMDs are reduced after completion of chemotherapy for ALL. The causes are multifactorial and mainly related to antineoplastic treatments, such as corticosteroids and methotrexate, physical inactivity and cranial irradiation. We suggest that further studies are needed to evaluate the long-term effect on BMD in these children and to prevent pathological fractures later in life.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16848106

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  8 in total

1.  Deregulation of the CXCL12/CXCR4 axis in methotrexate chemotherapy-induced damage and recovery of the bone marrow microenvironment.

Authors:  Kristen R Georgiou; Michaela A Scherer; Tristan J King; Bruce K Foster; Cory J Xian
Journal:  Int J Exp Pathol       Date:  2012-01-05       Impact factor: 1.925

Review 2.  Skeletal sequelae of cancer and cancer treatment.

Authors:  Charles J Stava; Camilo Jimenez; Mimi I Hu; Rena Vassilopoulou-Sellin
Journal:  J Cancer Surviv       Date:  2009-05-02       Impact factor: 4.442

3.  Bone turnover in long-term survivors of childhood acute lymphoblastic leukemia.

Authors:  Mitchell A Watsky; Laura D Carbone; Qi An; Cheng Cheng; Elizabeth A Lovorn; Melissa M Hudson; Ching-Hon Pui; Sue C Kaste
Journal:  Pediatr Blood Cancer       Date:  2014-03-20       Impact factor: 3.167

4.  Modifiable risk factors associated with bone deficits in childhood cancer survivors.

Authors:  Lynda E Polgreen; Anna Petryk; Andrew C Dietz; Alan R Sinaiko; Wendy Leisenring; Pam Goodman; Lyn M Steffen; Joanna L Perkins; Donald R Dengel; K Scott Baker; Julia Steinberger
Journal:  BMC Pediatr       Date:  2012-03-28       Impact factor: 2.125

5.  Bone mineral deficits in recipients of hematopoietic cell transplantation: the impact of young age at transplant.

Authors:  A Petryk; L E Polgreen; L Zhang; J S Hodges; D R Dengel; P A Hoffmeister; J Steinberger; K S Baker
Journal:  Bone Marrow Transplant       Date:  2013-10-14       Impact factor: 5.483

6.  Bone Mineral Density in Survivors of Childhood Acute Lymphoblastic Leukemia

Authors:  Farzaneh Rohani; Khadijeh Arjmandi Rafsanjani; Gholamreza Bahoush; Mansoureh Sabzehparvar; Mohammad Ahmadi
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

7.  Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.

Authors:  Rajen Mody; Suwen Li; Douglas C Dover; Stephen Sallan; Wendy Leisenring; Kevin C Oeffinger; Yutaka Yasui; Leslie L Robison; Joseph P Neglia
Journal:  Blood       Date:  2008-03-11       Impact factor: 25.476

8.  Potential Effects of Phytoestrogen Genistein in Modulating Acute Methotrexate Chemotherapy-Induced Osteoclastogenesis and Bone Damage in Rats.

Authors:  Tristan J King; Tetyana Shandala; Alice M Lee; Bruce K Foster; Ke-Ming Chen; Peter R Howe; Cory J Xian
Journal:  Int J Mol Sci       Date:  2015-08-06       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.